IL-18: A potential inflammation biomarker in Wiskott-Aldrich syndrome.

ABSTRACT: Analysis of serum cytokine levels in Wiskott-Aldrich syndrome patients pre- and post- treatment reveals IL-18 as a stable and reliable marker of inflammation. Definitive stem cell treatment with good myeloid correction correlates with resolution of inflammation and reduction of circulating IL-18, highlighting the importance of actin cytoskeletal regulation of myeloid cells in control of inflammation.

SUBMITTER: Rivers E 

PROVIDER: S-EPMC8436742 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature